SMMT
Summit Therapeutics Inc. Health Care Pharmaceutical Preparations Russell 3000
$16.03Close
$12.4BMarket cap
$12.43 – $26.3852-week range
Nov 2, 2026Next report
Highlights
Strengths
- Accumulation up-day volume 1.7× down-day volume over 50 sessions
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Far from its high 39% below its 52-week high
- Results soon Nov 2, 2026, in 1 day
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
39%
1wk
up 3.6%
price change
1mo
down 5.2%
price change
12-month return
down 14%
market up 11% ·
its own down 25%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
18.9×
price / book
Earnings yield
down 8.8%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 206%
return on equity
Free cash margin
—
-$323.6M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
5.8%
$0.93 a day · 2×ATR $14.16
RS
59 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
0.5×
vs 50-day average
Up/down volume
1.71
50 sessions
Implied move
—
no option chain · report Nov 2, 2026
Trend template · 1 of 8
- 150-day average above the 200-day: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 5.1% over the year, from 738m to 775m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Jul 23, 2026
Financials
- Net
- Free cash
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $860,000 | $1.8M | $705,000 | $0 | $0 | — |
| Operating income | -$53.2M | -$86.2M | -$72.1M | -$609.6M | -$226.0M | — |
| Net income | -$52.7M | -$88.6M | -$78.8M | -$614.9M | -$221.3M | -$1.1B |
| Net margin | -6128% | -4898% | -11175% | — | — | — |
| Earnings per share | -$0.15 | -$0.67 | -$0.41 | -$0.99 | -$0.31 | -$1.44 |
| Free cash flow | -$48.5M | -$72.9M | -$42.2M | -$76.9M | -$142.2M | -$323.6M |
| Free cash margin | -5643% | -4029% | -5987% | — | — | — |
| Cash | $66.4M | $71.8M | $348.6M | $71.4M | $104.9M | $225.3M |
| Long-term debt | — | — | $494.5M | $100.0M | $0 | — |
| Shareholders' equity | $79.5M | $83.3M | $126.7M | $77.7M | $388.7M | $658.9M |
| Shares outstanding | 412.88m | 98.04m | 211.09m | 701.66m | 737.63m | 775.37m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Jul 23, 2026 | Quarterly ↗ | Jun 30, 2026 | 23d |
| Apr 30, 2026 | Quarterly ↗ | Mar 31, 2026 | 30d |
| Feb 23, 2026 | Annual ↗ | Dec 31, 2025 | 54d |
| Oct 20, 2025 | Quarterly ↗ | Sep 30, 2025 | 20d |
| Aug 11, 2025 | Quarterly ↗ | Jun 30, 2025 | 42d |
| May 1, 2025 | Quarterly ↗ | Mar 31, 2025 | 31d |
| Feb 24, 2025 | Annual ↗ | Dec 31, 2024 | 55d |
| Oct 30, 2024 | Quarterly ↗ | Sep 30, 2024 | 30d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 1, 2024 | Quarterly ↗ | Mar 31, 2024 | 31d |
| Feb 20, 2024 | Annual ↗ | Dec 31, 2023 | 51d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 29, 2026 | Material agreement · Unregistered share sale · Charter or bylaws · Other events ↗ |
| Sep 15, 2026 | Other events ↗ |
| Sep 14, 2026 | Other events ↗ |
| Sep 3, 2026 | Other events ↗ |
| Aug 26, 2026 | Other events ↗ |
| Aug 5, 2026 | Other events ↗ |
| Jul 23, 2026 | Results · Regulation FD ↗ |
| Jul 23, 2026 | Material agreement ↗ |
| Jul 22, 2026 | Other events ↗ |
| Jun 12, 2026 | Shareholder vote ↗ |
| Jun 11, 2026 | Regulation FD ↗ |
| Jun 3, 2026 | Other events ↗ |